Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
Accessing GLP-1 receptor agonists specifically for fatty liver disease on the NHS can be challenging, as current prescribing pathways are primarily designed for diabetes and weight management rather than liver disease alone
Evidence From Clinical Literature and Real-World Practice Major weight loss trials for semaglutide (STEP 1-4 studies) achieved average weight reductions of 10-22% body weight over 68 weeks without phentermine combination, demonstrating robust monotherapy efficacy
Benefits Highly Stable Formulation Uses the stabilised L-carnitine fumarate ingredient
Its combined pro-angiogenic, cytoprotective, and anti-inflammatory properties make BPC-157 a promising research peptide for studies in regenerative medicine, vascular biology, and injury recovery
US$ 26.10
US$ 26.79
US$ 28.29
US$ 23.33
